Aptevo Therapeutics Inc. — Q1 2024 Form 10-Q
Business context and reporting period. This unaudited quarterly report covers the three months ended March 31, 2024. Aptevo is a clinical-stage biotechnology company developing immuno-oncology candidates, including clinical-stage APVO436 and ALG.APV-527. It reported no product revenue for the quarter.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Research and development expense | $3.8 million | $4.2 million |
| General and administrative expense | $3.2 million | $3.6 million |
| Loss from operations | $7.0 million | $7.8 million |
| Net loss / income | $6.8 million loss | $2.8 million income |
| Basic and diluted loss / income per share | $(9.95) | $17.38 |
| Net cash used in operating activities | $6.7 million | $4.6 million provided |
| Cash and cash equivalents at period end | $10.3 million | $16.9 million at Dec. 31, 2023 |
| Total current assets / current liabilities | $12.1 million / $6.3 million | At March 31, 2024 |
| Total assets / total liabilities / equity | $17.6 million / $11.5 million / $6.1 million | At March 31, 2024 |
The company reported no material financial debt in the presented quarter; liabilities include $5.2 million of operating lease obligations, with the lease extending through April 2030. No revenue or profit margin is reported, so revenue-based margins are not meaningful.
Material changes versus the prior comparable period
- Net results moved from income to loss, largely because Q1 2023 included a $9.7 million gain from selling certain Medexus payment rights to XOMA and $0.9 million of discontinued-operations income. Neither item recurred in Q1 2024.
- Operating expenses declined: R&D by approximately $0.4 million and G&A by approximately $0.4 million. Management attributed the R&D decrease mainly to lower APVO436, preclinical and employee costs, partly offset by higher ALG.APV-527 trial spending.
- Cash declined by $6.7 million during the quarter, principally reflecting operating cash use. The prior-year operating cash inflow included working-capital effects, including a $2.5 million royalty receivable change.
- Aptevo effected a 1-for-44 reverse stock split on March 5, 2024; share and per-share amounts in the filing reflect the split retroactively. It regained Nasdaq minimum bid-price compliance on March 20.
Outlook, risks and unusual items
- Going concern and funding: Management states that recurring operating losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern for the one-year period following issuance of the financial statements. The filing says substantial doubt exists through May 2025. Aptevo expects to need additional capital and warns that it may have to delay, scale back or eliminate development activities if funding is unavailable.
- Post-quarter financing: On April 10, 2024, Aptevo completed an offering generating $4.6 million gross and approximately $4.0 million net proceeds. It also issued warrants covering up to 6.8 million shares; exercise could provide up to a further $9.2 million, but would add dilution. The filing reports 4,080,169 common shares outstanding as of May 8, 2024.
- Pipeline: The company announced interim ALG.APV-527 Phase 1 dose-escalation data on March 7, 2024, but the filing text does not provide a clear numerical summary of the results. Planning continued for an APVO436 Phase 1b/2 dose-optimization trial in frontline AML with venetoclax and azacitidine, targeted for the first half of 2024.
- Other potential funding: Aptevo remains eligible for up to $5.8 million in Medexus milestones, contingent on regulatory and IXINITY sales thresholds. Timing and receipt are uncertain. Outstanding warrants could also generate proceeds if exercised.
- Key risks: The business depends on successful clinical development, regulatory approval, external trial and manufacturing providers, partnerships and access to capital. The filing also highlights potential dilution, competition, macroeconomic and supply-chain pressures, and continued Nasdaq listing requirements.
- Other disclosures: Management concluded disclosure controls were effective as of March 31, 2024 and reported no material change in internal control over financial reporting. Management said no pending legal matter was expected to have a material adverse effect.
Important facts for investors to verify
- Whether Aptevo obtains sufficient financing to address the stated going-concern uncertainty, and the cash runway implied by subsequent spending and funding.
- Progress, timing and costs for the APVO436 Phase 1b/2 trial and ALG.APV-527 Phase 1 program; review complete clinical data rather than interim disclosures.
- Whether Medexus achieves milestones that could provide Aptevo with cash, and the timing and amount of any payments.
- The dilution and proceeds implications of the April 2024 offering, its warrants and the warrants outstanding at March 31.
- Whether cash use, operating expenses and lease obligations change materially, and whether the company maintains Nasdaq listing compliance.